TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2201-2208

  Hashiguchi, Naoko ^a   Kubota, Tetsuro ^a   Koh, Jun Ichi ^b   Yamada, Yoshinori ^c   Saikawa, Yoshiro ^a   Otani, Yoshihide ^a   Watanabe, Masahiko ^a   Kumai, Koichiro ^a   Kitajima, Masaki ^a   Watanabe, Jun Ichi ^d   Kobayashi, Motohiro ^d  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA SOCIAL INSURANCE HOSPITAL   (Japan)

^c KITASATO INSTITUTE HOSPITAL   (Japan)

^d Grelan Pharmaceutical Co Ltd   (Japan)

Author keywords

Breast cancer; Nude mouse; TZT 1027; Vascular flow

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALTRETAMINE; ANTINEOPLASTIC AGENT; AURISTATIN PE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOLASTATIN 10; DOXORUBICIN; ESTRADIOL DIPROPIONATE; FLUOROURACIL; HYDROXYPROGESTERONE CAPROATE; IRINOTECAN; MITOMYCIN C; PACLITAXEL; PROTEIN P53; TAMOXIFEN; TUBULIN; UFT; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER; CANCER CELL CULTURE; CANCER MODEL; CELL STRAIN MCF 7; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MOUSE; NEUTROPENIA; NONHUMAN; NUDE MOUSE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERIZATION; PRIORITY JOURNAL; TUMOR BLOOD FLOW;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4444305445     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Miyaszaki K, Kobayashi M, Natsume T et al: Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull 43: 1706-1718, 1995.
2. Pettit GR, Kamano Y, Herald CL et al: The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. J Am Chem Soc 109: 6883-6885, 1987.
3. Kobayashi M, Natsume T, Tamaoki S et al: Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88: 316-327, 1997.
4. Watanabe J, Natsume T, Fujio N, Miyasaka K and Kobayashi M: Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 5: 345-353, 2000.
5. Soule HD, Varguez J, Long A, Albert S and Brennan M: Human cell line from pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973.
6. Kubota T, Kubouchi K, Koh J, Enomoto K, Ishibiki K and Abe O: Human breast carcinoma (MCF-7) serially transplanted into nude mice. Jpn J Surg 13: 381-383, 1983.
7. Nawata H, Bronzert D and Lippman ME: Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. J Biol Chem 256: 5016-5021, 1981.
8. Kubota T, Ishibiki K and Abe O: The clinical usefulness of human xenografts in nude mice. Prog Clin Biol Res 276: 213-225, 1988.
9. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
10. Shimoyama Y, Kubota T, Watanabe M, Ishibiki K and Abe O: Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to the clonogenic assay. J Surg Oncol 41: 12-18, 1989.
11. Suto A, Kubota T, Shimoyama Y, Ishibiki K and Abe O: MTT assay with reference to the clinical effect of chemotherapy. J Surg Oncol 42: 28-32, 1989.
12. Fujita K, Kubota T, Matsuzaki SW, Otani Y, Watanabe M, Teramoto T, Kumai K and Kitajima M: Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancer. Anticancer Res 18: 1973-1978, 1998.
13. Abe S, Kubota T, Matsuzaki SW, Otani Y, Watanabe M, Teramoto T, Kumai K and Kitajima M: Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for Stage III non-scirrhous gastric cancer. Anticancer Res 19: 4581-4586, 1999.
14. Geran RI, Greenberg NH, Macdonald MM, Schumacher AH and Abbott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (Third Edition). Cancer Chemother Rep (Part 3) 3: 51-61, 1972.
15. Kubota T, Nakada M, Tsuyuki K, Inada T, Asanuma F, Ishibiki K and Abe O: Cell kinetics and chemosensitivity of human carcinomas serially transplanted into nude mice. Jpn J Cancer Res 77: 502-507, 1986.
16. Kobayashi H, Higashiyama M, Minamigawa K, Tanisaka K, Takano T, Yokouchi H, Kodama K and Hata T: Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantification. Jpn J Cancer Res 92: 203-210, 2001.
17. Otani M, Natsume T, Watanabe JI, Kobayashi M, Murakoshi M, Mikami T and Nakayama T: TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 91: 837-844, 2000.
18. Matsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6393, 1986.
19. Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K and Tsukagoshi S: Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88: 316-327, 1997.
20. Koh J, Kubota T, Migita T, Abe S, Hashimoto M, Hosoda Y and Kitajima M: UCN-01 (7-hydroxystaurosporine) inhibits the growth of human cancer xenografts through disruption of signal transduction. Breast Cancer 9: 50-54, 2002.
21. Kubota T, Matsuzaki WS, Hoshiya Y, Watanabe M, Kitajima M, Asanuma F, Yamada Y and Koh J: Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J Surg Oncol 64: 115-121, 1997.
22. Fujita F, Koike M, Fujita M, Sakamoto Y and Tsukagoshi S: Antitumor effects of TZT-1027, a novel dolastatin 10 derivative, on human tumor xenografts in nude mice. Jpn J Cancer Chemother 27: 451-458, 2000. (in Japanese with English abstract)
23. Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K and Kobayashi M: Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res 91: 737-747, 2000.
24. Natsume T, Kobayashi M and Fujimoto S: Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma. Cancer 92: 386-394, 2001.
25. Yamamoto N, Andoh M, Kawahara M, Fukuoka M and Niitani H: Phase I study of TZT-1027, and inhibitor of tubulin polymerization, given weekly × 3 as a 1-hour intravenous infusion in patients with solid tumors. The 7th International Symposium on Cancer Chemotherapy "New Antitumor Agents under Development in US, Europe and Japan". pp. 26, 2002.